ArticleThe journal of liquid biopsy2026
Combined plasma and liquid-based cytology microRNA signatures as biomarkers of high-grade cervical lesions: association with HPV infection and p16 expression.
Article in The journal of liquid biopsy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNA (miRNA) dysregulation may provide complementary molecular information for cervical lesion assessment and triage. This prospective observational study evaluated six candidate miRNAs in paired plasma and liquid-based cytology (LBC) specimens and their associations with cytological severity, high-risk human papillomavirus (hrHPV), and p16 expression. Among 328 women, cytology was classified as normal (n = 52), atypical squamous cells of undetermined significance (ASC-US; n = 44), low-grade squamous intraepithelial lesion (LSIL; n = 42), high-grade squamous intraepithelial lesion (HSIL; n = 82), or squamous cell carcinoma (SCC; n = 108). hrHPV positivity increased from 0% in normal cytology to 93.5% in SCC and p16 positivity from 0% to 95.4% (both P < 0.001). In paired plasma and LBC specimens, miR-21-5p, miR-155-5p, miR-9-5p, and miR-15b-5p progressively increased with cytological severity, whereas miR-375-3p and miR-145-5p decreased (all p < 0.001). For discrimination of HSIL/SCC from normal/ASC-US/LSIL, individual-miRNA areas under the curve (AUCs) ranged from 0.970 to 0.993. After stratified 10-fold cross-validation, AUCs were 0.818 (95% CI, 0.765-0.869) for hrHPV, 0.807 (0.751-0.860) for p16, and 0.840 (0.789-0.888) for hrHPV + p16. The six-miRNA LBC panel achieved an AUC of 0.9999 (0.9996-1.000), 99.5% sensitivity, 100.0% specificity, and a Brier score of 0.006. These findings demonstrate strong internal discrimination by LBC-derived miRNAs; however, validation against histologically confirmed endpoints in independent, clinically representative populations is required before clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.